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Background.  Atrial fibrillation  is often asymptomatic but outcomes need further characterization. Aims. To 
investigate clinical presentation, management and outcomes in asymptomatic and symptomatic atrial 
fibrillation patients prospectively enrolled in the EurObservational Research Programme – Atrial Fibrillation 
(EORP-AF) Pilot General Registry. 
Results. A total of 3119 patients were enrolled, and 1237 (39.7%) were asymptomatic (EHRA score I). 
Among symptomatic patients, 963 (51.2%) had mild symptoms (EHRA score II) while 919 (48.8%) had 
severe or disabling symptoms (EHRA III-IV).  Permanent atrial fibrillation was threefold more common in 
asymptomatic than in symptomatic patients.    
On multivariate analysis, male gender (OR 1.630, 95% CI  1.384-1.921), older age (OR 1.019, 95% CI  
1.012-1.026), previous myocardial infarction (OR 1.681, 95% CI  1.350-2.093), and limited physical activity 
(OR 1.757, 95% CI  1.495-2.064) were significantly associated with asymptomatic (EHRA I) atrial 
fibrillation. 
Fully asymptomatic atrial fibrillation (absence of current and previous symptoms) was present in 520 
patients (16.7%), and was independently associated with male gender, age and previous myocardial 
infarction.   Appropriate guideline-based prescription of oral anticoagulants was lower in these patients, 
while aspirin was more frequently prescribed.  
In asymptomatic patients, mortality at 1 year was more than two-fold higher compared to symptomatic 
patients (9.4 vs. 4.2%, p<0.0001), and was independently associated with older age and comorbidities, 
including chronic kidney disease and chronic heart failure.   
Conclusions. Asymptomatic atrial fibrillation  is common in daily cardiology practice, being associated with 
elderly age and more co-morbidities, as well as high thromboembolic risks.  A higher 1-year mortality was 
found in asymptomatic compared to symptomatic patients. 
 














Atrial fibrillation  is often asymptomatic and there is growing interest in its clinical presentation, 
management and outcomes.(1-4). Atrial fibrillation is often detected in asymptomatic patients, and the 
arrhythmia may become asymptomatic over time or after treatment (5). Indeed, silent atrial fibrillation 
episodes are common and can be detected during clinical screening for various  reasons, continuous rhythm 
monitoring through an implanted device or during the diagnostic work up of patients presenting with 
cryptogenic stroke (6-9).  The burden of stroke across Europe remains important (10) and detection of an 
underlying atrial fibrillation, either symptomatic or asymptomatic,  has important implications not only in 
the perspective of  individual patients but also in the perspective of  public health systems (4, 11-13).   
The clinical presentation, associated co-morbidities and clinical management of atrial fibrillation  patients 
may change over time, according to increasing awareness on the potential risks associated with atrial 
fibrillation  , changes in population demography, evolution of treatments and more widespread 
implementation of evidence based guidelines (4, 14, 15). Therefore, a contemporary report of the current 
clinical presentation, management and outcomes in prospectively enrolled consecutive asymptomatic and 
symptomatic atrial fibrillation  patients managed by European cardiologists is timely, especially since new 
management guidelines were published by the European Society of Cardiology (ESC) in 2010, followed by 
a focused update in 2012 (16,  17). 
The objective of this article is to investigate clinical presentation, management and outcomes in 
asymptomatic and symptomatic atrial fibrillation  patients prospectively enrolled in the EurObservational 
Research Programme – Atrial Fibrillation (EORP-AF) Pilot General Registry (18-20). We tested the 
hypothesis that asymptomatic patients with atrial fibrillation  would have a worse prognosis compared to 
symptomatic patients, as the latter may receive better management given their symptomatic presentation.  
 
Methods 
The methods and baseline data from the EORP-AF Pilot General Registry have previously been published 
(18).  Patients’ enrollment started in early 2012.  One-year follow-up phase (‘pilot phase’ or Phase 1) data 
were focused on the initial 3119 patients recruited into this database, collected from 9 countries,  as a  valid 













In brief, the registry population comprised consecutive in- and out-patients presenting with atrial fibrillation  
to cardiologists, enrolled in 67 centres in 9 countries (18).  Consecutive patients were screened at the time of 
their presentation to a cardiologist (hospital or medical centre), and potential patients were approached to 
obtain written informed consent according to local rules.  Enrolment required ECG-confirmed diagnosis of 
atrial fibrillation  , with a qualifying episode of atrial fibrillation  documented in the 12 months prior to 
enrolment.   Stroke risk was categorized using the Congestive heart failure, Hypertension, 
Age 75, Diabetes, Stroke [Doubled] (CHADS2) score and the  Congestive heart failure, Hypertension, Age 
≥75 [Doubled], Diabetes, Stroke [Doubled]- Vascular disease, Age 65-74, and Sex category [female] 
(CHA2DS2-VASc) score (14, 16), whilst bleeding risk was categorized using the Hypertension, Abnormal 
renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly 
(>65 years), Drugs/ alcohol concomitantly (HAS-BLED)  score (14, 16). Patients were followed up to 1 year 
after enrollment (21). 
In this registry, a simple symptom score, proposed by the European Heart Rhythm Association (EHRA) 
(EHRA score) (16) was prospectively applied in order to quantify atrial fibrillation  -related symptoms and 
clearly distinguish fully asymptomatic patients from patients with variable degrees of impairment in daily 
activity.    
Specific data were collected on the degree of  physical activities reported by the patients. A limited , 
physical activity was defined as no exercise or exercise for < 3 hours/week for < 2years or exercise < 3 
hours/week for ≥ 2 years. 
 
Statistical analyses  
Univariate analysis was applied to both continuous and categorical variables. Continuous variables were 
reported as mean±SD and/or as median and Interquartile Range (IQR). Among-group comparisons were 
made using a non-parametric test (Kruskal-Wallis test). Categorical variables were reported as percentages. 
Among-group comparisons were made using a Chi-square test or a Fisher’s exact test if any expected cell 
count was less than five.  
Plots of the Kaplan-Meier curves for time to all-cause death in relation to EHRA symptoms subgroup were 













using the log-rank test. All the variables at entry which were statistically significant at univariate analysis 
and variables considered of relevant clinical interest were included in the multivariable model (logistic 
regression) to identify the variables independently associated with asymptomatic AF or with fully 
asymptomatic AF. Moreover, a multivariable model (logistic regression) was considered to identify the 
independent predictors of all-cause death, the composite of death or stroke/TIA/peripheral embolism  at  1-
year of follow-up.  
A two-sided p value of <0.05 was considered as statistically significant. All analyses were performed using 




A total of 3119 patients were enrolled, and at study entry 1237 (39.7%) were asymptomatic (EHRA score I). 
Among the 1882 patients who were symptomatic, 963 (51.2%) had mild symptoms (EHRA score II) while 
919 (48.8%) had severe or disabling symptoms (EHRA III-IV) [Table 1].  Compared to symptomatic atrial 
fibrillation  at enrollment, asymptomatic atrial fibrillation  was more commonly seen in specialized centers 
(72.6 vs. 59.4%, p<0.0001) and in an outpatient clinic or private cardiology practice (39.8 vs. 23.4%, 
p<0.0001).    
Clinical characteristics 
Asymptomatic atrial fibrillation  patients were older, more commonly males and with a higher proportion of 
concomitant diseases, including prior myocardial infarction and coronary revascularization (percutaneous 
transluminal coronary angioplasty/ coronary artery bypass graft. /) [Table 1]. A history of  thromboembolic 
complications and stroke were more common amongst asymptomatic patients.  
The type of atrial fibrillation  differed significantly (p<0.0001) between patients with symptomatic and 
asymptomatic atrial fibrillation  at enrollment. As shown in Figure 1, permanent atrial fibrillation  was 
threefold more common in asymptomatic atrial fibrillation  , while persistent atrial fibrillation  was two-fold 
more common in symptomatic patients. 
In patients with asymptomatic atrial fibrillation  , as compared with symptomatic atrial fibrillation  , the 













arrhythmia itself (43.2 vs. 71.3%), but more commonly heart failure (19.4 vs. 14.0%), myocardial infarction 
(7.1 vs.. 2.3%) or valvular heart disease (6.3 vs. 1.9%). 
In asymptomatic atrial fibrillation  heart rate at the ECG during atrial fibrillation  was lower than in 
symptomatic atrial fibrillation  , while on echocardiography left atrial size was larger and left ventricular 
hypertrophy less common [Table S1 supplementary material]. Risk scores for thromboembolic risk 
(CHA2DS2 and CHA2DS2-VASc), as well as bleeding risk (HAS-BLED) were higher in patients with 
asymptomatic atrial fibrillation  [Table 1]. 
On multivariate analysis, male gender (OR 1.630, 95% CI  1.384-1.921), older age (OR 1.019, 95% CI  
1.012-1.026), previous myocardial infarction (OR 1.681, 95% CI  1.350-2.093), and limited physical activity 
(OR 1.757, 95% CI  1.495-2.064) were significantly associated with asymptomatic (EHRA I)  atrial 
fibrillation  . 
Prescribed interventions and medications 
As expected, pharmacological and electrical cardioversion, antiarrhythmic drugs and left atrial ablation were 
less commonly employed in asymptomatic as compared to symptomatic atrial fibrillation  patients [Table S2 
supplementary material].  Rhythm control was more frequently applied to symptomatic patients, while 
simple observation was more commonly used in asymptomatic atrial fibrillation  (p< 0.0001 for the 
difference in management strategy) [Figure 2].  
When oral anticoagulants were indicated (ie, CHA2DS2-VASc ≥ 2 or cardioversion planned) oral 
anticoagulants were prescribed after admission/consultation in 81-83% of cases, independent from the 
presence/absence of atrial fibrillation  symptoms [Figure 2].   Non-vitamin K antagonist oral anticoagulants 
were more commonly prescribed in symptomatic patients. 
Fully asymptomatic atrial fibrillation   
The group of 1237 patients presenting at study entry with asymptomatic atrial fibrillation  has been split into 
a  subgroup of 520 ‘fully asymptomatic’ patients (ie. who previously never experienced atrial fibrillation  
symptoms)  and a subgroup of 717 patients with ‘asymptomatic atrial fibrillation  at study entry but with 
previous atrial fibrillation  symptoms’ [Table 2].  
Comparing these two subgroups, no differences were found with regard to observation in centers specialized 













(p=0.0076), with fully asymptomatic atrial fibrillation  patients less frequently seen in an outpatient clinic 
(27.7 vs. 35.1%). 
The clinical characteristics of enrolled fully asymptomatic patients are shown in Table 2. Median age as well 
as the proportion of elderly patients were higher in fully asymptomatic patients. In a more general view, 
considering the full cohort of patients, the relationship between age and symptoms appeared to be U-shaped 
since median age was the highest in fully asymptomatic atrial fibrillation  and the lowest in EHRA II [Table 
3] 
Less than one third of fully asymptomatic atrial fibrillation  patients were female, a lower rate than in 
asymptomatic patients with previous symptoms. In fully asymptomatic atrial fibrillation  patients, a history 
of myocardial infarction and percutaneous transluminal coronary angioplasty/ coronary artery bypass graft, 
chronic heart failure, chronic obstructive pulmonary dsease, history of  thromboembolic complications and 
stroke were more common than in fully asymptomatic atrial fibrillation patients.  
The type of atrial fibrillation  differed significantly (p<0.0001) between patients with fully symptomatic and 
asymptomatic atrial fibrillation  at enrollment but with previous symptoms. As shown in Figure 1, first-
detected atrial fibrillation  accounted for 41.1% of fully asymptomatic atrial fibrillation  , while paroxysmal 
atrial fibrillation  was less common. In patients with fully asymptomatic atrial fibrillation  , the reason for 
admission/consultation was significantly different (p<0.0001), being less commonly the arrhythmia itself 
(35.4 vs. 49.0%). 
Risk scores for thromboembolism (CHA2DS2 and CHA2DS2-VASc) and bleeding (HAS-BLED) were higher 
in fully asymptomatic atrial fibrillation  patients. Electrical cardioversion, antiarrhythmic drugs and left 
atrial ablation were less commonly employed in fully asymptomatic atrial fibrillation  patients, with rate 
control more frequently applied to fully asymptomatic patients [Figure 2 and Table S3 and S4 
supplementary material]. 
When oral anticoagulants were indicated, acccording to guidelines  (ie, CHA2DS2-VASc ≥  2 or 
cardioversion planned) oral anticoagulants were prescribed in a significantly lower proportion of fully 
asymtomatic patients, whilst aspirin was more frequently prescribed. Conversely, the proportion of use of 













On multivariate analysis (adjusting for male gender, age, previous myocardial infarction, CHA2DS2-VASc 
score, CHADS2 score, HAS-BLED score, limited physical activity and heart rate during atrial fibrillation) 
male gender (OR 1.658, 95% CI  1.286-2.138), older age  (OR 1.036, 95% CI  1.025-1.048), and previous 
myocardial infarction  (OR 1.630 (95% CI  1.215-2.188) were significantly associated with fully 
asymptomatic atrial fibrillation. 
Follow-up 
Mean follow-up was 366.4±31.8 days. One-year follow-up was available for 2642 of enrolled patients (10 
patients were dead at discharge and 467 patients, i.e. 15%,  were lost to follow-up).  
Asymptomatic atrial fibrillation (EHRA I) was associated with a significantly higher occurrence of death as 
compared with symptomatic atrial fibrillation, while the occurrence of cardiovascular  hospitalizations was 
significantly lower [Table 4]. Also the composite end point of stroke/transient ischemic attacks/peripheral 
embolism or death had a significantly higher occurrence in asymptomatic atrial fibrillation  patients. Kaplan-
Meier curves for survival for asymptomatic (EHRA I) and symptomatic (EHRA II-IV) atrial fibrillation 
patients are shown in Figure 3.  
On multivariate analysis,  older age (OR 1.062, 95% CI  1.041-1.083), chronic kidney disease (OR 3.099, 
95% CI  2.123-4.522),  chronic heart failure (OR 2.154, 95% CI  1.419-3.270), referral for reasons other 
than atrial fibrillation only (OR 2.121, 95% CI  1.374-3.273), minor bleeding (OR 2.138, 95% CI  1.210-
3.776),  previous transient ischemic attack (OR 2.327, 95% CI  1266-4.278),  chronic obstructive pulmonary 
disease (OR 1.669, 95% CI  1.078-2.583), malignancy (OR 1.896, 95% CI  1.049-3.428) were significantly 
associated with 1 year all-cause mortality, whilst a treatment with statins (OR 0.659, 95% CI  0.462-0.941) 
was associated with a lower mortality.    There was no significant association with EHRA I score (OR 1.424, 
95% CI  0.973-2.085). 
Moreover, on multivariate analysis, older age (OR 1.062, 95% CI  1.043-1.081), chronic kidney disease (OR 
2.688, 95% CI  1.885-3.832), chronic heart failure (OR 2.086, 95% CI  1.435-3.032), referral for reasons 
other than atrial fibrillation only (OR 2.322, 95% CI  1.567-3.441),  minor bleeding (OR 1.938, 95% CI  
1.129-3.330),  previous transient ischemic attack (OR 2.348, 95% CI  1.322-4.172) and  malignancy (OR 













ischemic attack, peripheral embolism or death’ at 1 year. There was no significant association with EHRA I 
score (OR 1.136, 95% CI  0.800-1.615). 
 
Discussion 
In this study our principal findings are first, 40% of atrial fibrillation  patients are asymptomatic and that 
among those with symptoms more than one half have mild symptoms (EHRA score II in 51.2%). Second, 
the prognostic implications of asymptomatic atrial fibrillation  are evident by our data showing that 
asymptomatic atrial fibrillation is not benign but is associated with an even higher mortality at 1 year as 
compared to symptomatic atrial fibrillation.  
Asymptomatic atrial fibrillation is common (1, 6, 11) and there is growing interest on its characterization in 
daily “real world” clinical practice. The EHRA symptoms classification, as originally proposed in ESC 
guidelines (16), is a valid mean of quantifying atrial fibrillation symptoms severity and correlates well with 
one disease-specific quality of life instrument (Atrial Fibrillation Effect on QualiTy-of-life, AFEQT 
Questionnaire)  and with another general measure for the health-related quality of life  (EQ-5D, 
incorporating the Visual Analog Scale, VAS) and  can be used to assess atrial fibrillation -related symptoms 
in clinical practice without prior training (22). 
In our cohort asymptomatic atrial fibrillation was predicted by male gender, age, previous myocardial 
infarction and  no physical activity and these may have practical implications in the perspective of screening 
strategies based on appropriate targeting of the population (11).  
The pattern of atrial fibrillation was not the same between symptomatic and asymptomatic patients, since 
permanent atrial fibrillation was around threefold more common in asymptomatic atrial fibrillation and 
persistent atrial fibrillation was around two-fold more common in symptomatic patients. In asymptomatic 
patients a lower use of resources, in terms of rate/rhythm control strategies and interventions, was applied 
and this was in accordance with current guidelines (16).   Heart rate during atrial fibrillation was on average 
around 20 beats/min lower in asymptomatic as compared with symptomatic atrial fibrillation and this 
finding, apart the therapeutic implications, may be important in interpreting the complex relationship 













While prescribed interventions and medications for rate/rhythm control differed between asymptomatic and 
symptomatic atrial fibrillation patients,  the scores for thromboembolic risk (CHA2DS and CHA2DS2-
VASc), as well as the HAS-BLED score were higher in patients with asymptomatic atrial fibrillation. 
However, detection of  asymptomatic atrial fibrillation resulted in around the same rate of  overall 
prescription of oral anticoagulants as compared to symptomatic patients, when indicated (ie, CHA2DS2-
VASc ≥ 2 or pharmacological cardioversion planned). The proportion of use of vitamin K antagonists and 
non-vitamin K antagonist oral anticoagulants differed, since non-vitamin K antagonist oral anticoagulants 
were more commonly prescribed in symptomatic patients, a finding that in part is  explained by the 
association between asymptomatic atrial fibrillation and prior myocardial infarction, suggesting preferential 
use of warfarin rather than non-vitamin K antagonist oral anticoagulants (24).  
Our study also focused on fully asymptomatic atrial fibrillation, who were compared with asymptomatic 
atrial fibrillation with previous symptoms. Fully asymptomatic atrial fibrillation is associated with the 
highest median age, as well as chronic heart failure (25).  Our data show that asymptomatic atrial fibrillation 
constitutes  a setting  where oral anticoagulants are still underused, despite the high mean CHADS2  and 
CHA2DS2-VASc scores among all atrial fibrillation symptom subgroups. The lower propensity to prescribe 
oral anticoagulants in fully asymptomatic atrial fibrillation patients could be related to the higher HAS-
BLED score (highest among all atrial fibrillation symptom subgroups) but this is a questionable decision 
making, since the reduced use of oral anticoagulants appears to be compensated by an increased use of 
antiplatelet agents, not justified by current guidelines and current evidence of benefit in terms of protection 
from the risk of stroke (1, 14, 16, 17, 26).   
 In the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial (27), 12% of 
patients did not report atrial fibrillation -related symptoms in the 6 months before study entry. In contrast to 
our cohort, coronary artery disease was more frequent in symptomatic vs. asymptomatic patients and at 5 
years a trend toward better survival in asymptomatic patients was observed, although mortality became 
similar after correction for baseline characteristics. In the more selected patients with persistent atrial 
fibrillation enrolled in the RAte Control versus Electrical cardioversion for persistent atrial fibrillation 













disease (28). During follow-up, the asymptomatic patients experienced fewer heart failure hospitalizations, 
but without significant differences in cardiovascular mortality.  
Our study shows that in asymptomatic patients, mortality at 1 year was more than 2-fold that of symptomatic 
patients. On multivariate analysis, age and co-morbidity rather than symptoms per se were independently 
associated with mortality at 1 year. Thus, in asymptomatic patients mortality is worse because the 
asymptomatic status is associated with older age and more co-morbidities, putting these patients at higher 
risk (29, 30).  The clinical implications of our findings in daily cardiology practice means recognition of 
asymptomatic atrial fibrillation should not decrease - but conversely, intensify patient care.     
 
Limitations 
Our study was based on an ongoing observational registry (18) but recruited consecutive patients seen by 
cardiologists, and the clinical picture of these patients cannot be generalized to those seen by internists, or 
general practitioner.  The registry was focused on European centers, belonging to  countries  with a different 
health care systems (31).    Also, follow-up was incomplete in 15% of patients.  
 
In conclusion, asymptomatic atrial fibrillation is common in daily cardiology practice, but its management 
is challenging, being associated with elderly age and more co-morbidities, as well as high thromboembolic 
and hemorrhagic risks.  A higher 1-year mortality was evident in asymptomatic atrial fibrillation compared 
to symptomatic atrial fibrillation. 
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Figure 1. Top panel: Type of AF at enrollment in symptomatic and asymptomatic AF patients (p<0.0001). 
Bottom panel: Type of AF at enrollment in fully asymptomatic AF patients and in asymptomatic patients 
with previous symptoms (p<0.0001). Legend: AF= atrial fibrillation. 
 
 
Figure 2. Panel A (on the left)  Therapeutic strategies used in asymptomatic vs. symptomatic patients. 
From top to bottom panel: management strategy (p<0.0001), antithrombotic treatment and type of oral 
anticoagulant when oral anticoagulants were indicated (ie, CHA2DS2-VASc ≥  2 or pharmacological 
cardioversion planned).  Panel B (on the right) Therapeutic strategies used in fully asymptomatic vs. 
previously symptomatic AF patients. From top to bottom panel: management strategy (p<0.0001), 
antithrombotic treatment and type of oral anticoagulant when oral anticoagulants were indicated (ie, 
CHA2DS2-VASc ≥  2 or pharmacological cardioversion planned). Legend: AF= atrial fibrillation, NOACs= 
non-vitamin K antagonist oral anticoagulants.  
 
 
















































































Legend: AF= atrial fibrillation, CABG= coronary artery bypass graft, CHADS2= Congestive heart failure, Hypertension, 
Age  75, Diabetes, Stroke [Doubled],  CHA2DS2-VASc = Congestive heart failure, Hypertension, Age ≥75 [Doubled], Diabetes, 
Stroke [Doubled]- Vascular disease, Age 65-74, and Sex category [female], HAS-BLED= Hypertension, Abnormal renal/liver 
function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly (>65 years), Drugs/ alcohol 
concomitantly ; NYHA= New York Heart Association, PTCA= percutaneous transluminal coronary angioplasty. 
 





EHRA II - IV P-value 
N° of patients 3119 1237 1882  
Demographics     
Age in years Median (IQR) 69 (62-77) 72 (64-78) 68 (61-76) <0.0001 
Age >= 75 yrs (%) 33.7 40.4 29.3 <0.0001 
Age > 65 yrs (%) 









Female gender (%) 40.4 35.0 43.9 <0.0001 
Concomitant disease (%)     
Lone AF 3.9 2.8 4.6 0.0115 
Coronary artery disease 36.3 40.1 33.8 0.0008 
Myocardial infarction 44.9 54.2 37.3 <0.0001 
PTCA/CABG 47.0 59.8 36.3 <0.0001 
Stable angina 37.4 30.5 43.1 <0.0001 
Chronic heart failure 47.5 44.3 49.6 0.0044 
of whom NYHA III/IV 41.5 45.9 38.9 0.0098 
Valvular heart disease 63.4 64.5 62.7 0.2976 
Dilated cardiomyopathy 11.5 9.4 12.9 0.0037 
Hypertrophic cardiomyopathy 3.9 2.4 4.9 0.0004 
Restrictive cardiomyopathy 0.5 0.9 0.2 0.0085 
Hypertensive heart disease 19.5 14.5 22.8 <0.0001 
Other cardiac disease 8.3 10.1 7.0 0.0034 
Chronic obstructive pulmonary disease 11.0 12.1 10.2 0.0997 
Hyperthyroidism 3.0 2.1 3.6 0.0158 
Hypothyroidism 7.2 7.3 7.2 0.8664 
Chronic kidney disease 13.1 15.6 11.5 0.0011 
Peripheral vascular disease 11.0 13.0 9.7 0.0041 
Cardiovascular risk factors (%)     
Diabetes 20.6 22.3 19.4 0.0548 
Hypertension 70.7 70.1 71.1 0.5202 
Current smoker 11.1 10.0 11.9 0.1075 
Hypercholesterolaemia 48.4 46.9 49.4 0.1714 
Alcohol >= 2-3/day 7.8 9.6 6.6 0.0028 
Physical activity (%)     
None 39.2 48.0 33.4 <0.0001 
Occasional 34.9 31.5 37.0  
Regular 21.3 17.0 24.2  
Intense 4.6 3.5 5.3  
Co-morbidities (%)     
Ischaemic thrombo-embolic 
complications 
13.1 14.8 11.9 0.0184 
Previous stroke 6.3 7.7 5.4 0.0082 
Previous Transient Ischaemic Attack 4.1 4.9 3.6 0.0707 
Haemorrhagic events 5.8 8.3 4.2 <0.0001 
Haemorrhagic stroke 5.0 4.9 5.1 >0.999[a] 
Major bleeding 27.6 29.4 25.3 0.5411 
Malignancy 5.4 5.5 5.2 0.7472 
CHADS2 score     
    Mean score ± SD 1.92 ±1.27 2.00 ±1.31 1.87 ±1.25 0.0145 
    Two or more 60.3 62.2 59.0  
CHA2DS2- VASc score     
    Mean score ± SD 3.24 ±1.79 3.41 ±1.78 3.14 ±1.79 <0.0001 
   Two or more 81.7 84.7 79.7  
HAS-BLED score     
   Mean score ± SD 1.37 ±1.06 1.46 ±1.04 1.31 ±1.07 <0.0001 
   Two or more 40.7 44.1 38.4  
     















Table 2.  Patient characteristics at enrollment in fully asymptomatic patients and in asymptomatic 







N° of patients 520 717  
Demographics    
Age in years Median (IQR) 74 (67-80) 70 (62-77) <0.0001 
Age >= 75 yrs (%) 48.8 34.3 <0.0001 
Age > 65 yrs (%) 78.1 66.0 <0.0001 
Age < =50 yrs (%) 4.4 5.9 0.2643 
Female gender (%) 29.8 38.8 0.0011 
Concomitant disease (%)    
Lone AF 1.3 3.9 0.0074 
Coronary artery disease 42.9 38.0 0.0977 
Myocardial infarction 65.8 44.4 <0.0001 
PTCA/CABG 67.3 53.5 0.0032 
Stable angina 24.3 35.7 0.0093 
Chronic heart failure 49.7 40.3 0.0012 
CHF of whom NYHA III/IV 49.8 42.4 0.0882 
Valvular heart disease 66.1 63.4 0.3295 
Dilated cardiomyopathy 10.8 8.4 0.1483 
Hypertrophic cardiomyopathy 1.4 3.1 0.0558 
Restrictive cardiomyopathy 0.6 1.2 0.3708[a] 
Hypertensive cardiomyopathy 14.9 14.3 0.7926 
Other cardiac disease 10.3 10.0 0.8562 
Chronic obstructive pulmonary disease 16.0 9.3 0.0005 
Hyperthyroidism 2.2 2.0 0.8508 
Hypothyroidism 7.0 7.6 0.7269 
Chronic kidney disease 17.4 14.2 0.1307 
Peripheral vascular disease 15.8 11.0 0.0154 
Cardiovascular risk factors (%)    
Diabetes 24.7 20.6 0.0906 
Hypertension 71.5 69.0 0.3435 
Current smoker 11.1 9.2 0.2713 
Hypercholesterolaemia 46.0 47.5 0.5892 
Alcohol >= 2-3/day 12.5 7.6 0.0054 
Physical activity (%)    
None 52.9 44.3 0.0226 
Occasional 27.6 34.5  
Regular 15.8 17.8  
Intense 3.7 3.4  
Co-morbidities (%)    
Ischaemic thrombo-embolic complications 17.3 13.0 0.0375 
Previous stroke 8.5 7.2 0.3972 
Previous Transient Ischaemic Attack 6.4 3.8 0.0382 
Haemorrhagic events 9.1 7.7 0.3793 
Haemorrhagic stroke 4.3 5.5 >0.999[a] 
Major bleeding 31.9 27.3 0.6080 
Malignancy 4.5 6.2 0.1967 
CHADS2 score    
    Mean score ± SD 2.18 ±1.32 1.87 ±1.28 <0.0001 
    Two or more 68.3 57.9  
CHA2DS2- VASc score    
Mean score ± SD 3.71 ±1.78 3.19 ±1.76 <0.0001 
Two or more 89.6 81.2  
HAS-BLED score    
Mean score ± SD 1.61 ±1.05 1.36 ±1.03 <0.0001 















a]: Fisher exact test. 
Legend: AF= atrial fibrillation,  CABG= coronary 
artery bypass graft,, CHADS2= Congestive heart 
failure, Hypertension, Age ≥ 75, Diabetes, Stroke 
[Doubled],  CHA2DS2-VASc = Congestive heart 
failure, Hypertension, Age ≥75 [Doubled], 
Diabetes, Stroke [Doubled]- Vascular disease, 
Age 65-74, and Sex category [female],  CHF= 
chronic heart failure, HAS-BLED= Hypertension, 
Abnormal renal/liver function, Stroke, Bleeding 
history or predisposition, Labile international 
normalized ratio, Elderly (>65 years), Drugs/ 
alcohol concomitantly,  NYHA= New York Heart 
Association, PTCA= percutaneous transluminal 
coronary angioplasty. 














                             
 




EHRA I but 
previous 
symptoms EHRA II EHRA III EHRA IV P-value 
N° of patients 520 717 963 746 173  
Demographics       
Age in years 
Median (IQR) 
74 (67-80) 70 (62-77) 67 (60-74) 69 (61-77) 71 (61-78) <0.0001 
























EHRA I  EHRA II-IV  P-Values 
Mortality 102/1086 (9.4%) 65/1556 (4.2%) <0.0001 
Cardiovascular 
hospitalisations 226/949 (23.8%) 396/1334 (29.7%) 0.0019 
Stroke/TIA/Peripheral 
embolism 10/962 (1.0%) 15/1344 (1.1%) 0.8610 
Stroke/TIA/Peripheral 
embolism or Death 112/1064 (10.5%) 80/1409 (5.7%) <0.0001 
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IQR=Interquartile range, ICD=Implantable cardioverter-defibrillator,  
BBB: bundle branch block; LA: left atrial; LVEF: left ventricular ejection fraction; LVH: left ventricular 
hypertrophy.  






Table S1. Patient history and result of clinical evaluation at enrollment 





EHRA II - IV P-value 
N° of patients 3119 1237 1882  
     
Previous interventions     
Pharmacological cardioversion 36.3 23.3 44.6 <0.0001 
Electrical cardioversion 28.7 27.8 29.2 0.4094 
Catheter ablation 7.7 6.5 8.5 0.0460 
Pacemaker implantation 6.9 8.6 5.8 0.0034 
ICD implantation 1.5 2.6 0.7 <0.0001 
AF surgery 0.9 0.9 0.9 0.9675 
 
Body Mass Index (kg/m²) 27 (25-31) 27 (25-30) 28 (25-31) 0.0234 
Systolic Blood Pressure(mmHg) 130 (120-142) 130 (120-140) 130 (120-150) <0.0001 
Diastolic Blood Pressure(mmHg) 80 (70-87) 80 (70-80) 80 (70-90) <0.0001 
     
Electrocardiogram     
QRS duration (ms) (Median (IQR)) 98 (82-110) 100 (87-118) 96 (80-109) <0.0001 
Left BBB (%) 53.8 54.6 53.0 0.7531 
Right BBB (%) 46.2 45.4 47.0  
Heart rate (bpm)(Median (IQR))     
during AF 92 (76-119) 82 (71-98) 100 (80-125) <0.0001 
in sinus rhythm 67 (58-77) 66 (57-77) 68 (59-78) 0.2178 
Echocardiogram     
LA size (mm)(Median (IQR)) 44 (40-50) 47 (41-53) 43 (39-48) <0.0001 
LVEF (%)(Median (IQR)) 55 (45-60) 55 (44-60) 55 (45-60) 0.6672 
LVH (%) 31.3 26.5 34.4 <0.0001 















































EHRA II - IV P-value 
N° of patients 3119 1237 1882  
     
Interventions (%)     
N (on inpatients only) 1994 669 1325  
Pharmacological cardioversion 30.0 13.9 38.1 <0.0001 
Electrical cardioversion 22.9 15.4 26.8 <0.0001 
Catheter ablation 9.1 6.0 10.7 0.0006 
Pacemaker implantation 4.3 4.2 4.3 0.8979 
ICD Implantation 1.2 2.0 0.8 0.0185 
Surgical therapy 0.3 0.1 0.3 0.6692[a] 
Drug prescriptions     
Antiarrhythmic drugs (%)     
At least one 35.7 26.4 41.8 <0.0001 
Amiodarone 21.3 13.0 26.7 <0.0001 
Beta-blockers 69.4 69.6 69.3 0.8885 
Digoxin 19.7 18.6 20.4 0.1948 
ACE inhibitors 43.2 46.0 41.4 0.0102 
ARBs 21.8 19.7 23.1 0.0233 
Diuretics 50.6 55.1 47.6 <0.0001 




IQR=Interquartile range, ICD=Implantable cardioverter-defibrillator, ACE: angiotensin converting enzyme; ARV: 
angiotensin receptor blockers.  


























N° of patients 520 717  
    
Previous interventions    
Pharmacological cardioversion 13.4 30.8 <0.0001 
Electrical cardioversion 17.6 35.4 <0.0001 
Catheter ablation 1.8 9.9 <0.0001 
Pacemaker implantation 6.9 9.8 0.0782 
ICD implantation 2.1 2.9 0.3736 
AF surgery 1.0 0.8 >0.999[a] 
    
Body Mass Index (kg/m²) 27 (24-30) 27 (25-30) 0.0949 
Systolic Blood Pressure(mmHg) 130 (120-140) 130 (120-140) 0.8294 
Diastolic Blood Pressure(mmHg) 80 (70-80) 80 (70-81) 0.3411 
    
Electrocardiogram    
QRS duration (ms) (Median (IQR)) 100 (86-117) 100 (88-118) 0.4387 
Left BBB (%) 44.9 61.9 0.0221 
Right BBB (%) 55.1 38.1  
Heart rate (bpm)(Median (IQR))    
during AF 82 (70-96) 83 (72-100) 0.0731 
in sinus rhythm 70 (63-82) 64 (57-75) 0.0047 
Echocardiogram    
LA size (mm)(Median (IQR)) 47 (43-53) 46 (40-54) 0.3450 
LVEF (%)(Median (IQR)) 54 (40-60) 57 (45-61) 0.0006 
LVH (%) 28.5 25.0 0.1994 
    
 
IQR=Interquartile range, ICD=Implantable cardioverter-defibrillator,  
BBB: bundle branch block; LA: left atrial; LVEF: left ventricular ejection fraction; LVH: left ventricular 
hypertrophy.  






















N° of patients 520 717  
    
Interventions (%)    
N (on inpatients only) 285 384  
Pharmacological cardioversion 11.6 15.6 0.1409 
Electrical cardioversion 9.5 19.8 0.0002 
Catheter ablation 1.4 9.4 <0.0001 
Pacemaker implantation 3.2 4.9 0.2529 
ICD Implantation 2.5 1.6 0.4160 
Surgical therapy 0.4 0 0.4266[a] 
Antiarrhythmic drugs (%)    
At least one 17.7 32.7 <0.0001 
Amiodarone 13.5 12.7 0.6886 
Beta-blockers 70.0 69.3 0.7788 
Digoxin 18.3 18.7 0.8671 
ACE inhibitors 48.8 44.0 0.0918 
ARBs 18.9 20.3 0.5613 
Diuretics 59.8 51.7 0.0044 
Aldosterone blockers 34.4 23.6 <0.0001 
 
 
IQR=Interquartile range, ICD=Implantable cardioverter-defibrillator,  
BBB: bundle branch block; LA: left atrial; LVEF: left ventricular ejection fraction; LVH: left ventricular 
hypertrophy.  
















• In the EORP AF General Pilot Registry, focused on cardiology practice, 
asymptomatic AF  was common - accounting for around 40% of AF cases 
consecutively collected.   .   Permanent AF was threefold more common in 
asymptomatic than in symptomatic patients.    
• Male gender, older age, previous MI, and limited physical activity were 
significantly associated with asymptomatic AF. 
• Asymptomatic AF is associated with a higher mortality compared to  
symptomatic AF. 
 
